Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo

Cancer Gene Therapy

Volumn 15, Issue 3, 2008, Pages 193-202

  He, X W ^a   Liu, T ^b   Chen, Y X ^a   Cheng, D J ^a   Li, X R ^a   Xiao, Y ^a   Feng, Y L ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CaCO3 nanoparticles; Gastric carcinoma; Nonviral vector; RNA interference; Vascular endothelial growth factor c

Indexed keywords

CALCIUM CARBONATE; DNA; LIPOSOME; MESSENGER RNA; SMALL INTERFERING RNA; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DEGRADATION; DNA TRANSFER; DOWN REGULATION; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; ELECTRICITY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; SURFACE PROPERTY; TARGET CELL; TUMOR XENOGRAFT;

ANIMALS; CALCIUM CARBONATE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PLASMIDS; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 39049157474     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701122     Document Type: Article

References (40)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin 2003; 53: 5-26.
2. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191.
3. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 672-682.
4. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 151-152.
5. Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999; 5: 1823-1829.
6. Tsurusaki T, Kanda S, Sakai H, Kanetake H, Saito Y, Alitalo K et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999; 80: 309-313.
7. Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000; 83: 887-891.
8. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000; 6: 2431-2439.
9. Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL et al. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin Cancer Res 2000; 6: 4278-4286.
10. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 2001; 85: 255-260.
11. Hashimoto I, Kodama J, Seki N, Hongo A, Yoshinouchi M, Okuda H et al. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer 2001; 85: 93-97.
12. Kitadai Y, Amioka T, Haruma K, Tanaka S, Yoshihara M, Sumii K et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001; 93: 662-666.
13. McManus MT, Sharp PA. Gene silencing in mammals by small interfering. Nat Rev Genet 2002; 3: 737-747.
14. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002; 26: 199-213.
15. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.
16. Shi Y. Mammalian RNAi for the masses. Trends Genet 2003; 19: 9-12.
17. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8: 681-686.
18. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-247.
19. Blaesé M, Blankenstein T, Brenner M, Cohen-Haguenauer O, Gansbacher B, Russeu S et al. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther 1995; 2: 291-297.
20. Yang Y, Nunes FA, Berenncsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenovirus for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
21. Engelhardt JE, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
22. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 2003; 3: 545-565.
23. Han S, Mahato RI, Sung YK, Kin SW. Development of biomaterials for gene therapy. Mol Ther 2000; 2: 302-317.
24. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999; 237: 1-30.
25. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 672-682.
26. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002; 296: 1811-1812.
27. Kaipanien A, Korhonen J, Mustonen T, Van Hinsberqh VW, Fang GH, Dumont D et al. Expression of the fms-like tyrosine kinase 4 gene become restricted to lymphatic endothelium during development. Proc Natl Sci USA 1995; 92: 3566-3570.
28. Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 2003; 63: 3593-3597.
29. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003; 63: 1515-1519.
30. Wannenes F, Ciafre SA, Niola F, Frajese G, Farace MG. Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo. Cancer Gene Ther 2005; 12: 926-934.
31. Lapteva N, Yang AG, Sanders DE, Strube DE, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2004; 12: 84-89.
32. Stege A, Priebsch A, Nieth C, Lage H. Stable and complete overcoming of MDR1/p-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther 2004; 11: 696-700.
33. Xu XM, Wang D, Shen Q, Chen YQ, Wang MH. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 2004; 23: 8464-8474.
34. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004; 23: 8486-8496.
35. Bigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54: 631-651.
36. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Pol(lactic acid)-poly(ethylene glycol) nanoparticles as new carries for the delivery of plasmid DNA. Control Release 2001; 75: 211-224.
37. Liu T, Tang AF, Zhang Gy, Yu Xiang C, Zhang JY, Shu Song P et al. Calcium phosphate nanoparticles as a novel nonviral vector efficiently transfection of DNA in cancer gene therapy. Cancer Biother Radiopharm 2005; 20: 141-149.
38. Truong-Le VL, Walsh SM, Schweibert E, Mao HQ, Guggino WB, August JT et al. Gene transfer by DNA-gelatin nanospheres. Arch Biochem Biophys 1999; 361: 47-56.
39. Cohen Y, Levv RJ, Gao J, Fishbein I, Kousae V, Sosnowski S et al. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Therapy 2007; 7: 1896-1905.
40. Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Rev Mol Diagn 2005; 5: 893-905.